SRX Global Inc美股招股说明书(2026-07-16版)

SRX Global Inc. Up to 3,125,752 Shares of Common StockOffered by the Selling Stockholders This prospectus supplement updates and supplements the information contained in the prospectus dated December 31, 2025 (as may be supplemented or amended from time to time, the “Prospectus”),which forms part of our registration statement on Form S-1 (File No. 333-291395), as amended, with the information contained in our Current Reports on Forms 8-K which were filed with the Securitiesand Exchange Commission on June 18, 2026, June 24, 2026, June 26, 2026, July 10, 2026, July 15, 2026 and July 16, 2026 (the “Current Reports”). Accordingly, we have attached each of the CurrentReports to this prospectus supplement. This prospectus relates to the resale from time to time by the selling stockholders named in this prospectus (collectively, the “Selling Stockholders”) or their permitted transferees (after the expiration ofany applicable lock-up period, assuming the satisfaction of any applicable vesting conditions and subject to the beneficial ownership and stock exchange limitations described herein), of up to 3,125,752shares of our common stock, par value $0.0001 per share (“Common Stock”) which consists of (a) 48,343 shares of our common stock issuable upon the exercise of warrants to purchase Common Stock(“July Warrants”), purchased by certain investors pursuant to the Securities Purchase Agreement, dated July 7, 2025, (the “July PIPE SPA”) (the “July PIPE Financing”); (b) 2,856,226 shares of ourcommon stock which represents 200% of the 519,316 shares of our common stock issuable upon the conversion of shares of our Series A Convertible Preferred Stock, par value $0.0001 (the “Series APreferred Stock”) and 908,797 shares of our common stock issuable upon exercise of warrants to purchase Common Stock (“October Warrants”), purchased by certain investors pursuant to the SecuritiesPurchase Agreement, dated October 27, 2025, (the “October PIPE SPA”) (the “October PIPE Financing”); (c) 8,194 shares of our common stock issuable in exchange for shares of the capital stock ofSRx Health Solutions (Canada), Inc. (“SRx Canada”), a corporation organized under the laws of Ontario, Canada which are exchangeable for shares of our Common Stock on a one-for-one basis (the“Exchangeable Shares”); (d) 67,279 shares of our common stock, which were issued to certain other investors in private placement on April 24, 2025 (the “Private Placement”); (e) 63,210 shares of ourcommon stock, which were issued to certain service providers in consideration of service provided (the “Service Provider Shares”); and (f) 82,500 shares of our common stock, which were issued toHalo Spin-Out SPV Inc. (“Spin-Out SPV”) pursuant to a Share Exchange Agreement (the “Exchange Agreement”) by and between the Company and SPV dated August 21, 2025 (such transaction, the“Share Exchange”). For more information about the Common Stock offered for resale by the Selling Stockholders pursuant to this prospectus, including the purchase prices paid by such SellingStockholders for their securities, see “Information Related to Offered Securities” beginning on page 8 of this prospectus. The share numbers provided above have been adjusted to reflect the 60-for-1 reverse stock split which took effect on July 6, 2026. You should read the prospectus. this prospectus supplement and any additional prospectus supplement or amendment carefully before you invest in our securities. Our Common Stock is listed on the NYSE American under the symbol “SRXH”. On July 15, 2026, the closing price of our Common Stock was $2.310 per share. We are a “smaller reporting company” under applicable federal securities laws and will be subject to reduced public company reporting requirements for so long as we remain a smallerreporting company. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under this prospectus or determined if thisprospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is July 15, 2026. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 CURRENT REPORT Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter). If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standardsprovided pursuant to Section 13(a) of the Exchange Act.☐ Item 7.01. Regulation FD Disclosure. Closing of Share Exchange Transaction On June 18, 2026, SRx Health Solutions, Inc. (NYSE: SRXH) (the “Company”) issued a press release (the “Press Release”) announcin